Skip to content

Merck & Co. MRK Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Pfizer logo
PfizerPFE
$90.1B-0.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Cytokinetics logo
CytokineticsCYTK
-$826.57M-210%
Phibro Animal Health logo
Phibro Animal HealthPAHC
$361.83M+36.0%

Other financials

Income statement

See full
Revenue$16.3B+4.9%
Gross profit$12.1B-0.2%
Net income-$4.2B-183%
EPS (diluted)-$1.72-186%

Balance sheet

See full
Cash & equivalents$5.4B-38.2%
Total debt$49.1B+35.8%
Total assets$128.69B+11.8%

Cash flow

See full
Operating cash flow$3.9B+56.7%
CapEx$991.0M-25.4%
Free cash flow$2.9B+150%

Valuation

See full
Market cap$314.83B+52.6%
Enterprise value$358.53B+52.5%
P/E35.2×+22.7×
P/S4.8×+1.5×

Profitability

See full
Gross margin73.9%-2.5pp
Net margin13.6%-13.7pp
FCF margin21.5%-5.2pp

Returns & leverage

See full
Return on equity19%-20.3pp
Debt / equity1.1×+0.3×
Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Merck & Co.'s total equity?
Merck & Co. (MRK) reported total equity of $45.88B in Q1 2026.
How has Merck & Co.'s total equity changed year-over-year?
Merck & Co.'s total equity decreased by 5.1% year-over-year, from $48.34B to $45.88B.
What is the long-term trend for Merck & Co.'s total equity?
Over 5 years (2020 to 2025), Merck & Co.'s total equity has grown at a 15.8% compound annual growth rate (CAGR), from $25.32B to $52.61B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.